University of Groningen, Groningen University Institute for Drug Exploration (GUIDE), Department of Social Pharmacy, Pharmacoepidemiology & Pharmacotherapy, Groningen, The Netherlands.
Expert Rev Pharmacoecon Outcomes Res. 2006 Apr;6(2):215-27. doi: 10.1586/14737167.6.2.215.
Vaccination represents the single most cost-effective strategy to avert influenza-related morbidity, mortality and economic consequences. This review presents an analysis of the pharmacoeconomic aspects of influenza vaccination of the elderly. The methodology of the analysis focuses on the main drivers of the pharmacoeconomic profile of elderly influenza vaccination, in particular the vaccine effectiveness in terms of prevention of hospitalization and mortality, the background incidence of hospitalization and death in unvaccinated individuals and the relative costing of the vaccine compared with the costs of a hospital in-patient day. The variation in outcomes between different studies could partly be explained by differences in the main drivers defined above. This review demonstrates that the pharmacoeconomic profile of elderly influenza vaccination is highly favorable. From the vast majority of studies it appears that financial benefits of elderly influenza vaccination surpass the costs and that, when this is not the case, cost-effectiveness in terms of net costs per life-year gained is acceptable.
接种疫苗是避免流感相关发病率、死亡率和经济后果的最具成本效益的策略。本综述分析了老年人流感疫苗接种的药物经济学方面。分析的方法侧重于老年人流感疫苗接种药物经济学特征的主要驱动因素，特别是疫苗在预防住院和死亡方面的有效性、未接种疫苗人群的住院和死亡的背景发生率，以及疫苗相对于住院日费用的相对成本。不同研究结果之间的差异部分可以用上述主要驱动因素的差异来解释。本综述表明，老年人流感疫苗接种的药物经济学特征非常有利。从绝大多数研究来看，老年人流感疫苗接种的经济效益似乎超过了成本，而在这种情况下，每获得一个生命年的净成本的成本效益是可以接受的。
